TP53 and medulloblastoma: Subgrouping was performed in 66/89 patients and EFS showed a trend toward a poorer outcome for the 15 patients with SHH-tumors (2 with constitutional TP53-mutations) versus patients with group 3 and 4 (#51) medulloblastoma (15-year EFS: 45.7%, 95% CI: 26.1%–80.2% vs 69.8%, 58.1%–83.9% CI: P = .065; Figure 4).